

DT07 Rec'd PCT/PTO 26 NOV 2004

PATENT

Attorney Reference Number 6395-64909-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 10/500,796

Filed: July 6, 2004

Confirmation No. 5091

For: NUCLEIC ACID VACCINES FOR  
PREVENTION OF FLAVIVIRUS  
INFECTION

Examiner:

Art Unit:

Attorney Reference No. 6395-64909-02

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney  
for Applicant(s)

Date Mailed November 23, 2004

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement  
☒ Form 1449 and 118 references cited thereon

*(No references enclosed)*

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

By

Tanya M. Harding, Ph.D.  
Registration No. 42,630

cc: Docketing



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

Application No. 10/500,796

Filed: July 6, 2004

Confirmation No. 5091

For: NUCLEIC ACID VACCINES FOR  
PREVENTION OF FLAVIVIRUS  
INFECTION

Examiner:

Art Unit:

Attorney Reference No. 6395-64909-02

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney  
for Applicant(s)

Date Mailed November 23, 2004

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicant will provide copies of such patents or applications upon request.

Applicant filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicant to file this IDS,


please charge any such fees, or credit overpayment, to the Deposit Account referenced on the attached Transmittal Letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Tanya M. Harding, Ph.D.  
Registration No. 42,630

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing

10 Rest. Filing 26 NOV 2004

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6395-64909-02
	Application Number	10/500,796
	Filing Date	July 6, 2004
	First Named Inventor	Chang
	Art Unit	
	Examiner Name	

**U.S. PATENT DOCUMENTS**

U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Date	Name of Applicant or Patentee
		4,810,492	03/07/89	Fujita <i>et al.</i>
		5,021,347	06/04/91	Yasui <i>et al.</i>
		5,229,293	07/20/93	Matsuura <i>et al.</i>
		5,494,671	02/27/96	Lai <i>et al.</i>
		5,514,375	05/07/96	Paoletti <i>et al.</i>
		6,074,865	06/13/20	Kelly <i>et al.</i>
		6,136,561	10/24/00	Ivy <i>et al.</i>
		6,165,477	12/26/00	Ivy <i>et al.</i>
		6,258,788	07/10/01	Schmaljohn
		6,455,509	09/24/02	Kochel <i>et al.</i>

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 90/01946	03/08/90	
		WIPO	WO 92/02548	02/20/92	
		WIPO	WO 92/03545	03/05/92	
		WIPO	WO 93/06214	04/01/93	

EXAMINER  
SIGNATURE:DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10 FEB 2005

26 NOV 2004

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Attorney Docket Number		6395-64909-02
				Application Number		10/500,796
				Filing Date		July 6, 2004
				First Named Inventor		Chang
				Art Unit		
				Examiner Name		
		WIPO	WO 98/37911	09/03/98		
		WIPO	WO 99/06068	02/11/99		
		WIPO	WO 99/63095	12/09/99		
		WIPO	WO 02/072036	09/19/02		
		WIPO	WO 02/083903	10/24/02		
		JAPAN	JP 89025725 (English Abstract only)	May 1989		
		JAPAN	JP 5276941 (English Translation)	10/26/93		
		JAPAN	JP 53133627 (English Abstract only)	November 1978		
		JAPAN	JP 63004895 (English Abstract only)	1963		
		JAPAN	JP 63105682 (English Abstract only)	05/10/88		
		JAPAN	JP 65000611 (English Abstract only)	1965		
		JAPAN	JP 67025408 (English Abstract only)	1967		
		JAPAN	JP 7265093 (English Abstract only)	October 1995		
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS				
		Aberle <i>et al.</i> , "A DNA Immunization Model Study with Constructs Expressing the Tick-Borne Encephalitis Virus Envelope Protein E in Different Physical Forms," <i>J Immunology</i> 163:6756-6761 (1999).				
		Allison <i>et al.</i> , "Synthesis and Secretion of Recombinant Tick-Borne Encephalitis Virus Protein E in Soluble and Particulate Form," <i>J Virology</i> 69(9):5816-5820 (September 1995).				

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	6395-64909-02
		Application Number	10/500,796
		Filing Date	July 6, 2004
		First Named Inventor	Chang
		Art Unit	
		Examiner Name	
		Alvarez <i>et al.</i> , "A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients," <i>Hum. Gene Ther.</i> 8:229-242 (January 20, 1997).	
		Anderson <i>et al.</i> , "Isolation of West Nile Virus from Mosquitoes, Crows, and a Cooper's Hawk in Connecticut," <i>Science</i> 286(5448):2331-2333 (Dec. 17, 1999).	
		Asnis <i>et al.</i> , "The West Nile Virus Outbreak of 1999 in New York: The Flushing Hospital Experience," <i>Clin. Infect. Dis.</i> 30: 413-418 (2000).	
		Azevedo <i>et al.</i> , "Main features of DNA-based immunization vectors," <i>Braz. J. Med. Biol. Res.</i> 32(2):147-153 (1999).	
		Bray <i>et al.</i> , "Mice Immunized with Recombinant Vaccinia Virus Expressing Dengue 4 Virus Structural Proteins with or without Nonstructural Protein NSI Are Protected Against Fatal Dengue Virus Encephalitis," <i>J. Virol.</i> 63(6):2853-2856 (June 1989).	
		Cavener and Ray, "Eukaryotic start and stop translation sites," <i>Nucleic Acids Research</i> , 19(12):3185-3192 (1991).	
		Chang <i>et al.</i> , "A Single Intramuscular Injection of Recombinant Plasmid DNA Induces Protective Immunity and Prevents Japanese Encephalitis in Mice," <i>J. Virol.</i> 74(9):4244-4252 (May 2000).	
		Chang <i>et al.</i> , "Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus," <i>Virology</i> , 306:170-180 (2003).	
		Chang <i>et al.</i> , "Flavivirus DNA Vaccines," <i>Annals New York Academy of Sciences</i> , 951:272-285 (2001).	
		Chang <i>et al.</i> , "Recent advancement in flavivirus vaccine development," <i>Expert Rev. Vaccines</i> , 3(2):199-220 (2004).	
		Chen <i>et al.</i> , "Construction of Intertypic Chimeric Dengue Viruses Exhibiting Type 3 Antigenicity and Neurovirulence for Mice," <i>J Virology</i> , 69(8):5186-5190 (August 1995).	
		Clarke <i>et al.</i> , "Techniques for Hemagglutination And Hemagglutination-Inhibition With Arthropod-Borne Viruses," <i>Amer. J. Trop. Med. And Hyg.</i> , 7:561-573 (1958).	
		Colombage <i>et al.</i> , "DNA-Based and Alphavirus-Vectored Immunisation with PrM and E Proteins Elicits Long-Lived and Protective Immunity against the Flavivirus, Murray Valley Encephalitis Virus," <i>Virology</i> 250:151-163 (1998).	
		Davis <i>et al.</i> , "West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses in Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme- Linked Immunosorbent Assays," <i>J. Virol.</i> 75(9):4040-4047, 2001 (published on-line April 4, 2001).	

EXAMINER  
SIGNATURE:DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10 Rec'd  
26 NOV 2004

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	6395-64909-02
		Application Number	10/500,796
		Filing Date	July 6, 2004
		First Named Inventor	Chang
		Art Unit	
		Examiner Name	
		Deubel <i>et al.</i> , "Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Type 2 Virus, Jamaica Genotype," <i>Virology</i> 155:365-377 (1986).	
		Deubel <i>et al.</i> , "Nucleotide Sequence and Deduced Amino Acid Sequence of the Nonstructural Proteins of Dengue Type 2 Virus, Jamaica Genotype: Comparative Analysis of the Full-Length Genome," <i>Virology</i> 165:234-244 (1988).	
		Dmitriev <i>et al.</i> , "Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis," <i>J. Biotechnol.</i> 44:97-103 (1996).	
		Duarte dos Santos <i>et al.</i> , "Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213," <i>Virus Res.</i> 35:35-41 (1995).	
		Falgout <i>et al.</i> , "Proper Processing of Dengue Virus Nonstructural Glycoprotein NSI Requires the N-Terminal Hydrophobic Signal Sequence and the Downstream Nonstructural Protein NS2a," <i>J. Virol.</i> 63(5):1852-1860 (May 1989).	
		Falgout <i>et al.</i> , "Immunization of Mice with Recombinant Vaccinia Virus Expressing Authentic Dengue Virus Nonstructural Protein NSI Protects Against Lethal Dengue Virus Encephalitis," <i>J. Virol.</i> 64(9):4356-4363 (1990).	
		Fonseca <i>et al.</i> , "Recombinant vaccinia viruses co-expressing dengue-1 glycoprotein prM and E induce neutralizing antibodies in mice," <i>Vaccine</i> 12(3):279-285 (1994).	
		Garmendia <i>et al.</i> , "Recovery and Identification of West Nile Virus from a Hawk in Winter," <i>J. Clin. Microbiol.</i> 38(8):3110-3111 (August 2000).	
		Gruenberg <i>et al.</i> , "Partial Nucleotide Sequence and Deduced Amino Acid Sequence of the Structural Proteins of Dengue Virus Type 2, New Guinea C and PUO-218 Strains," <i>J. Gen. Virol.</i> , 69:1391-1398 (1988).	
		Guirakhoo <i>et al.</i> , "Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus is Immunogenic and Protective in Nonhuman Primates," <i>J. Virol.</i> , 74(12):5477-5485 (2000).	
		Hahn <i>et al.</i> , "Nucleotide Sequence of Dengue 2 RNA and Comparison of the Encoded Proteins with Those of Other Flaviviruses," <i>Virology</i> 162:167-180 (1988).	
		Hashimoto <i>et al.</i> , "Molecular Cloning and Complete Nucleotide Sequence of the Genome of Japanese Encephalitis Virus Beijing-1 Strain," <i>Virus Genes</i> 1(3):305-317 (1988).	
		Heinz <i>et al.</i> , "Flaviviruses." In <i>Immunochemistry of Viruses II: The Basis for Serodiagnosis and Vaccines</i> . (edited by von Regenmortel and Neurath) Elsevier Science Publishers, Chapter 14, pp. 89-305 (1990).	
		Henchal <i>et al.</i> , "Dengue Virus-Specific And Flavivirus Group Determinants Identified With Monoclonal Antibodies By Indirect Immunofluorescence," <i>Amer. J. Trop. Med. Hyg.</i> 31:830-836 (1982).	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	6395-64909-02
		Application Number	10/500,796
		Filing Date	July 6, 2004
		First Named Inventor	Chang
		Art Unit	
		Examiner Name	
		Hennessy <i>et al.</i> , "Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study," <i>Lancet</i> 347:1583-1586 (June 8, 1996).	
		Ho <i>et al.</i> , "DNA vaccination induces a long-term antibody response and protective immunity against pseudorabies virus in mice," <i>Arch Virol</i> , 143:115-125 (1998).	
		Hubálek <i>et al.</i> , "West Nile Fever-a Reemerging Mosquito-Borne Viral Disease in Europe," <i>Emerg. Infect. Dis.</i> , 5(5):643-650 (1999).	
		Hunt <i>et al.</i> , "A recombinant particulate antigen of Japanese encephalitis virus produced in stably-transformed cells is an effective noninfectious antigen and subunit immunogen," <i>J. Virological Methods</i> , 97:133-149 (2001).	
		Hunt and Calisher, "Relationships of Bunyamwera Group Viruses by Neutralization," <i>Amer. J. Trop. Med. Hyg.</i> , 28(4):740-749 (1979).	
		Jacobs <i>et al.</i> , "High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model," <i>J. Virol.</i> , 66(4):2086-2095 (April 1992).	
		Jacobs, "A novel recombinant adenovirus vector expressing a flavivirus non-structural protein protects against lethal flavivirus challenge," <i>Clinical Science</i> , 85:117-122 (1993).	
		Jia <i>et al.</i> , "Genetic analysis of West Nile New York 1999 encephalitis virus," <i>Lancet</i> , 354:1971-1972 (December 4, 1999).	
		Johnson <i>et al.</i> , "Detection of Anti-Arboviral Immunoglobulin G by Using a Monoclonal Antibody-Based Capture Enzyme-Linked Immunosorbent Assay," <i>J. Clin. Microbiol.</i> , 38(5):1827-1831 (May 2000).	
		Kimura-Kuroda and Yasui, "Antigenic Comparison of Envelope Protein E between Japanese Encephalitis Virus and Some Other Flaviviruses Using Monoclonal Antibodies," <i>J. Gen. Virol.</i> , 67:2663-2672 (1986).	
		Kimura-Kuroda and Yasui, "Topographical Analysis of Antigenic Determinants on Envelope Glycoprotein V3 (E) of Japanese Encephalitis Virus, Using Monoclonal Antibodies," <i>J. Virol.</i> , 45(1):124-132 (January 1983).	
		Klinman <i>et al.</i> , "CpG motifs as immune adjuvants," <i>Vaccine</i> , 17:19-25 (1999).	
		Kochel <i>et al.</i> , "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," <i>Vaccine</i> , 15(5):547-552 (1997).	
		Köhler <i>et al.</i> , "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , 256:495-497 (August 7, 1975).	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	6395-64909-02
		Application Number	10/500,796
		Filing Date	July 6, 2004
		First Named Inventor	Chang
		Art Unit	
		Examiner Name	
		Konishi <i>et al.</i> , "A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice," <i>Vaccine</i> 18:1133-1139 (2000).	
		Konishi <i>et al.</i> , "Comparison of Protective Immunity Elicited by Recombinant Vaccinia Viruses That Synthesize E or NS1 of Japanese Encephalitis Virus," <i>Virology</i> , 185:401-410 (1991).	
		Konishi <i>et al.</i> , "Avipox virus-vectored Japanese encephalitis virus vaccines: use a vaccine candidates in combination with purified subunit immunogens," <i>Vaccine</i> , 12(7):633-638 (1994).	
		Konishi <i>et al.</i> , "Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles," <i>J. Virol.</i> 75(5):2204-2212 (March 2001).	
		Konishi <i>et al.</i> , "The Anamnestic Neutralizing Antibody Response Is Critical for Protection of Mice from Challenge following Vaccination with a Plasmid Encoding the Japanese Encephalitis Virus Premembrane and Envelope Genes," <i>J. Virology</i> 73(7):5527-5534 (July 1999).	
		Konishi <i>et al.</i> , "Induction of Protective Immunity against Japanese Encephalitis in Mice by Immunization with a Plasmid Encoding Japanese Encephalitis Virus Premembrane and Envelope Genes," <i>J Virology</i> , 72(6):4925-4930 (June 1998).	
		Konishi <i>et al.</i> , "Mice Immunized with a Subviral Particle Containing the Japanese Encephalitis Virus prM/M and E Proteins Are Protected from Lethal JEV Infection," <i>Virology</i> , 188:714-720 (1992).	
		Kozak, "Circumstances and Mechanisms of Inhibition of Translation by Secondary Structure in Eucaryotic mRNAs," <i>Mol. Cell. Biol.</i> , 9(11):5134-5142 (November 1989).	
		Kozak, "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," <i>J. Mol. Biol.</i> , 196:947-950 (1987).	
		Kozak, "Point Mutations Define a Sequence Flanking the AUG Initiator Codon That Modulates Translation by Eukaryotic Ribosomes," <i>Cell</i> , 44:283-292 (January 31, 1986).	
		Kuno <i>et al.</i> , "Phylogeny of the Genus Flavivirus," <i>J. Virol.</i> , 72(1):73-83 (January 1998).	
		Laemmli, "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4," <i>Nature</i> , 227:680-685 (August 15, 1970).	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

6 NOV 2004

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Attorney Docket Number	6395-64909-02
			Application Number	10/500,796
			Filing Date	July 6, 2004
			First Named Inventor	Chang
			Art Unit	
			Examiner Name	
		Lai <i>et al.</i> , "Immunization of Monkeys with Baculovirus Recombinant-expressed Dengue Envelope and NSI Glycoproteins Induces Partial Resistance to Challenge with Homotypic Dengue Virus," In <i>Vaccines 90: Modern Approaches to New Vaccines including Prevention of AIDS</i> , Cold Spring Harbor Laboratory, Cold Springs Harbor, NY, pp. 119-124 (1990).		
		Lanciotti <i>et al.</i> , Origin of the West Nile Virus Responsible for an Outbreak of Encephalitis in the Northeastern United States," <i>Science</i> , 286:2333-2337 (December 17, 1999).		
		Lin <i>et al.</i> , "DNA Immunization with Japanese Encephalitis Virus Nonstructural Protein NS1 Elicits Protective Immunity in Mice," <i>J. Virol.</i> , 72(1):191-200 (January 1998).		
		Mackow <i>et al.</i> , "The Nucleotide Sequence of Dengue Type 4 Virus: Analysis of Genes Coding for Nonstructural Proteins," <i>Virology</i> , 159:217-228 (1987).		
		Mandl <i>et al.</i> , "Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic Elements in Tick-Borne Versus Mosquito-Borne Flaviviruses," <i>Virology</i> , 194:173-184 (1993 ).		
		Martin <i>et al.</i> , "Standardization of Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assays for Routine Diagnosis of Arboviral Infections," <i>J. Clin. Microbiol.</i> , 38(5):1823-1826 (May 2000 ).		
		Mason <i>et al.</i> , "Sequence of the Dengue-1 Virus genome in the Region Encoding the Three Structural Proteins and the Major Nonstructural Protein NS1," <i>Virology</i> , 161:262-267 (1987).		
		Mason <i>et al.</i> , "Japanese Encephalitis Virus-Vaccinia Recombinants Produce Particulate Forms of the Structural Membrane Proteins and Induce High Levels of Protection against Lethal JEV Infection," <i>Virology</i> , 180:294-305 (1991).		
		Mir <i>et al.</i> , "High-efficiency gene transfer into skeletal muscle mediated by electric pulses," <i>Proc. Nat. Acad. Sci. USA</i> , 96:4262-4267 (April 1999).		
		Monath, "Flavivirus," <i>Virology (R.N. Fields, ed.)</i> , 763-814 (1990).		
		Nitayaphan <i>et al.</i> , "Nucleotide Sequence of the Virulent SA-14 Strain of Japanese Encephalitis Virus and Its Attenuated Vaccine Derivative, SA-14-14-2," <i>Virology</i> , 177:541-552 (1990).		
		Osatomi and Sumiyoshi, "Complete Nucleotide Sequence of Dengue Type 3 Virus Genome RNA," <i>Virology</i> , 176:643-647 (1990).		
		Osatomi <i>et al.</i> , "Nucleotide Sequence of Dengue Type 3 Virus Genomic RNA Encoding Viral Structural Proteins," <i>Virus Genes</i> , 2(1):99-108 (1988).		

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	6395-64909-02
		Application Number	10/500,796
		Filing Date	July 6, 2004
		First Named Inventor	Chang
		Art Unit	
		Examiner Name	
		Phillpotts <i>et al.</i> , "Immunization with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus," <i>Arch. Virol.</i> 141:743-749 (1996).	
		Pincus <i>et al.</i> , "Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis," <i>Virology</i> , 187:290-297 (1992).	
		Porter <i>et al.</i> , "Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses," <i>Arch. Virol.</i> 143:997-1003 (1998).	
		Ramelow <i>et al.</i> , "Detection of tick-borne encephalitis virus RNA in ticks ( <i>Ixodes ricinus</i> ) by the polymerase chain reaction," <i>J. Virol. Meth.</i> , 45:115-9 (1993).	
		Raviprakash <i>et al.</i> , "Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein," <i>Vaccine</i> 18:2426-2434 (2000).	
		Rice <i>et al.</i> , "Nucleotide Sequence of Yellow Fever Virus: Implications for Flavivirus Gene Expression and Evolution," <i>Science</i> , 229:726-733 (August 23, 1985).	
		Roehrig <i>et al.</i> , "Identification of Epitopes on the E Glycoprotein of Saint Louis Encephalitis Virus Using Monoclonal Antibodies," <i>Virology</i> , 128:118-126 (1983).	
		Roehrig <i>et al.</i> , "Synthetic Peptides Derived from the Deduced Amino Acid Sequence of the E-Glycoprotein of Murray Valley Encephalitis Virus Elicit Antiviral Antibody," <i>Virology</i> , 171:49-60 (1989).	
		Sato <i>et al.</i> , "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," <i>Science</i> , 273(5273):352-354 (July 19, 1996).	
		Schalich <i>et al.</i> , "Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions," <i>J. Virol.</i> , 70:4549-4557 (July 1996).	
		Schimaljohn <i>et al.</i> , "Naked DNA Vaccines Expressing the prM and E Genes of Russian Spring Summer Encephalitis Virus and Central European Encephalitis Virus Protect Mice from Homologous and Heterologous Challenge," <i>J. Virology</i> 71(12):9563-9569 (December 1997).	
		Seeger <i>et al.</i> , "The cloned genome of ground squirrel hepatitis virus is infectious in the animal," <i>Proc Natl Aca Sci U.S.A.</i> , 81(18):5849-4852 (September 1984).	
		Sela, <i>The Choice of Carrier. Synthetic Vaccines Volume I</i> (edited by Arnon) CRC Press Inc, Boca Raton, FL., pp. 83-92 (1987).	
		Simmons <i>et al.</i> , "Short Report: Antibody Responses of Mice Immunized with a Tetravalent Dengue Recombinant Protein Subunit Vaccine," <i>Am. J. Trop. Med. Hyg.</i> 65(2):159-161 (2001).	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Attorney Docket Number	6395-64909-02
		Application Number	10/500,796
		Filing Date	July 6, 2004
		First Named Inventor	Chang
		Art Unit	
		Examiner Name	
		Smithburn <i>et al.</i> , "A Neurotropic Virus Isolated From the Blood Of A Native of Uganda," <i>Am. J. Trop. Med. Hyg.</i> , 20:471-492 (1940).	
		Sumiyoshi <i>et al.</i> , "Complete Nucleotide Sequence of the Japanese Encephalitis Virus Genome RNA," <i>Virology</i> , 161:497-510 (1987).	
		Tardei <i>et al.</i> , "Evaluation of Immunoglobulin M (IgM) and IgG Enzyme Immunoassays in Serologic Diagnosis of West Nile Virus Infection," <i>J. Clin. Microbiol.</i> 38(6):2232-2239 (June 2000).	
		Trent <i>et al.</i> , "Partial Nucleotide Sequence of St. Louis Encephalitis Virus RNA: Structural Proteins. NS1 ns2a and ns2b," <i>Virology</i> , 156:293-304 (1987).	
		Tsai <i>et al.</i> , "Japanese Encephalitis Vaccines. In Vaccines (2 <sup>nd</sup> edition) (edited by Plotkin and Mortimer), W.B. Saunders Co., Philadelphia, PA, Chapter 24, pp. 671-713 (1994).	
		Tsai <i>et al.</i> , "Japanese Encephalitis Vaccines. In Vaccines (3 <sup>rd</sup> edition) (edited by Plotkin and Orenstein), W.B. Saunders Co., Philadelphia, PA, Chapter 27, pp. 672-710 (1999).	
		Venugopal <i>et al.</i> , "Immunity to St. Louis encephalitis virus by sequential immunization with recombinant vaccinia and baculovirus derived PrM/E proteins," <i>Vaccines</i> , 13(11):1000-1005 (1995).	
		Wang <i>et al.</i> , "Immunization of Mice Against West Nile Virus with Recombinant Envelope Protein," <i>J. Immunol.</i> 167:5273-5277 (2001).	
		Wang <i>et al.</i> , "Immune Response to Neonatal Genetic Immunization," <i>Virology</i> , 228:278-284 (1997).	
		Wolff <i>et al.</i> , "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle," <i>Hum Mol Genet</i> , 1(6):363-369 (September 1992).	
		Yang <i>et al.</i> , "A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A," <i>Nature</i> , 382:319-324 (July 25, 1996).	
		Yasui <i>et al.</i> , "Analysis of Japanese encephalitis (JE) virus genome and implications for recombinant JE vaccine," <i>Southeast Asian J. Trop. Med. Public Health</i> , 21(4):663-669 (1990).	
		Zhang <i>et al.</i> , "Immunization of Mice with Dengue Structural Proteins and Nonstructural Protein NSI Expressed by Baculovirus Recombinant Induces Resistance to Dengue Virus Encephalitis," <i>J. Virol.</i> , 62(8):3027-3031 (August 1988).	
		Zhang <i>et al.</i> , "Passive Protection of Mice, Goats, and Monkeys Against Japanese Encephalitis With Monoclonal Antibodies," <i>J. Med. Virol.</i> , 29:133-138 (1989).	
		Zhao <i>et al.</i> , "Cloning Full-Length Dengue Type 4 Viral DNA Sequences: Analysis of Genes Coding for Structural Proteins," <i>Virology</i> , 155:77-88 (1986).	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Attorney Docket Number	6395-64909-02
			Application Number	10/500,796
			Filing Date	July 6, 2004
			First Named Inventor	Chang
			Art Unit	
			Examiner Name	
		Zhao <i>et al.</i> , "Expression of Dengue Virus Structural Proteins and Nonstructural Protein NS <sub>1</sub> by a Recombinant Vaccinia Virus," <i>J. Virol.</i> , 61(12):4019-4022 (December 1987).		
		"Update: Surveillance for West Nile Virus in Overwintering Mosquitoes --- New York, 2000," <i>Morb. Mortal. Wkly. Rep.</i> , 49(09):178-179 (March 10, 2000).		
		"Update: West Nile Virus Activity --- Northeastern United States, 2000," <i>Morb. Mortal. Wkly. Rep.</i> , 49(36):820-822 (September 15, 2000).		

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	